HROW
Harrow, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website arrow.com
- Employees(FY) 217
- ISIN US4158581094
Performance
-11.23%
1W
-10.65%
1M
-32.85%
3M
+24.19%
6M
-11.09%
YTD
+213.01%
1Y
Profile
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Technical Analysis of HROW 2025-02-03
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-10-02 11:10
Harrow, Inc. (HROW): A Bull Case Theory(Insider Monkey)
- 2024-09-25 12:02
Harrow Announces Nashville Expansion(Business Wire)
- 2024-09-25 00:02
Harrow Announces Nashville Expansion(Businesswire)
- 2024-09-19 07:06
Three US Growth Companies With High Insider Ownership(Simply Wall St.)
- 2024-09-03 07:00
- 2024-09-02 19:00
- 2024-08-07 16:01
Harrow Announces Second Quarter 2024 Financial Results(Business Wire)
- 2024-08-07 04:01
Harrow Announces Second Quarter 2024 Financial Results(Businesswire)
- 2024-07-25 07:00
- 2024-07-24 19:00
- 2024-07-12 07:00
Harrow to Attend 2024 ASRS Annual Meeting(Business Wire)
- 2024-07-11 19:00
Harrow to Attend 2024 ASRS Annual Meeting(Businesswire)
- 2024-07-09 07:00
- 2024-07-08 19:00
- 2024-07-01 23:52
- 2024-06-20 07:00
Harrow Provides TRIESENCE® Relaunch Update(Business Wire)
- 2024-06-19 19:00
Harrow Provides TRIESENCE Relaunch Update(Businesswire)
- 2024-06-06 18:30
The Top 7 Growth Stocks to Buy and Hold Until 2030(Investorplace)
- 2024-06-06 08:00
- 2024-06-05 20:00
- 2024-06-05 07:00
- 2024-06-04 19:00
- 2024-05-15 07:00
Harrow to Present at Two Investor Conferences in May(Business Wire)
- 2024-05-14 19:00
Harrow to Present at Two Investor Conferences in May(Businesswire)
- 2024-05-13 16:01
Harrow Announces First Quarter 2024 Financial Results(Business Wire)
- 2024-05-13 08:55
- 2024-05-13 07:00
- 2024-05-13 04:25
- 2024-05-13 04:01
Harrow Announces First Quarter 2024 Financial Results(Businesswire)
- 2024-05-12 19:00
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.